Effects of albendazole combined with TSII-A (a Chinese herb compound) on optic neuritis caused by Angiostrongylus cantonensis in BALB/c mice

Parasites and Vectors

Volumn 8, Issue 1, 2015, Pages

  Feng, Feng ^a,b   Feng, Ying ^a   Liu, Zhen ^a,b   Li, Wei Hua ^c   Wang, Wen Cong ^c   Wu, Zhong Dao ^a,b   Lv, Zhiyue ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Albendazole combined with TSII A; Angiostrongylus cantonensis; BALB c mice; Optic neuritis

Indexed keywords

ALBENDAZOLE; CRYPTOTANSHINONE; DEXAMETHASONE; TANSHINONE IIA; ABIETANE DERIVATIVE; ANTIINFECTIVE AGENT; HERBACEOUS AGENT; TANSHINONE;

ANGIOSTRONGYLIASIS; ANGIOSTRONGYLUS CANTONENSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CELL INFILTRATION; CONTROLLED STUDY; DEMYELINATION; DRUG EFFECT; EVOKED VISUAL RESPONSE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MOUSE; NERVE FIBER; NONHUMAN; OPTIC NERVE; OPTIC NEURITIS; RETINA; RETINA GANGLION CELL; STAINING; SWELLING; TRANSMISSION ELECTRON MICROSCOPY; VISUAL ACUITY; ANIMAL; COMBINATION DRUG THERAPY; DISEASE MODEL; DRUG EFFECTS; PARASITOLOGY; STRONGYLIDA INFECTIONS;

ALBENDAZOLE; ANGIOSTRONGYLUS CANTONENSIS; ANIMALS; ANTI-INFECTIVE AGENTS; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DITERPENES, ABIETANE; DRUG THERAPY, COMBINATION; DRUGS, CHINESE HERBAL; MICE; MICE, INBRED BALB C; OPTIC NEURITIS; STRONGYLIDA INFECTIONS;

EID: 84947941961     PISSN: None     EISSN: 17563305     Source Type: Journal    
DOI: 10.1186/s13071-015-1214-6     Document Type: Article

References (23)

1. Malhotra SMD, Arora R, Chauhan D, Ray S, Jain M. Ocular angiostrongyliasis in a child - first case report from India. J Trop Pediatr. 2000;52(3):223-5.
2. Ketsuwan PPA. Second case of ocular angiostrongyliasis in Thailand. Am J Trop Med Hyg. 1966;15(1):50-1.
3. Liu IH, Chung YM, Chen SJ, Cho WL. Necrotizing retinitis induced by Angiostrongylus cantonensis. Am J Ophthalmol. 2006;141(3):571-9.
4. Wang LCWI, Jou JR. Optic neuritis secondary to Angiostrongylus cantonensis infection. Ocul Immunol Inflamm. 2006;14(3):189-91.
5. Feng Y, Nawa Y, Sawanyavisuth K, Lv Z, Wu ZD. Comprehensive review of ocular angiostrongyliasis with special reference to optic neuritis. Korean J Parasitol. 2013;51(6):613-9.
6. Punyagupta S, Juttijudata P, Bunnag T. Eosinophilic meningitis in Thailand. Clinical studies of 484 typical cases probably caused by Angiostrongylus cantonensis. Am J Trop Med Hyg. 1975;24:921-31.
7. Sawanyawisuth K. Treatment of angiostrongyliasis. Trans R Soc Trop Med Hyg. 2008;102(10):990-6.
8. Diao Z, Wang J, Qi H, Li X, Zheng X, Yin C. Human ocular angiostrongyliasis: a literature review. Trop Doct. 2011;41(2):76-8.
9. Feng Y, Zeng X, Li WH, Wang WC, Chen W, Ou-Yang LS, et al. The pathogenesis of optic neuritis caused by Angiostrongylus cantonensis in BALB/c mice. Parasite Vector. 2014;7(1):339.
10. Feng Y, Zeng X, Li WH, Wang WC, Ou-Yang LS, Sun X, et al. Animal model of human disease with optic neuritis: neuropapillitis in a rat model infected with Angiostrongylus cantonensis. Parasitol Res. 2014;113(11):4005-13.
11. Xu S, Liu P. Tanshinone II-A: new perspectives for old remedies. Expert Opinion Therapeutic Patents. 2013;23(2):149-53.
12. Tian XH, Wu JH. Tanshinone derivatives: a patent review (January 2006 - September 2012). Expert Opinion Therapeutic Patents. 2013;23(1):19-29.
13. Lee JC, Park JH, Park OK, Kim IH, Yan BC, Ahn JH, et al. Neuroprotective effects of tanshinone I from Danshen extract in a mouse model of hypoxia-ischemia. Anatomy & Cell Biol. 2013;46(3):183-90.
14. Tang Q, Han R, Xiao H, Li J, Shen J, Luo Q. Protective effect of tanshinone IIA on the brain and its therapeutic time window in rat models of cerebral ischemia-reperfusion. Experim Therap Med. 2014;8(5):1616-22.
15. Park JH, Park OK, Yan B, Ahn JH, Kim IH, Lee JC, et al. Neuroprotection via maintenance or increase of antioxidants and neurotrophic factors in ischemic gerbil hippocampus treated with tanshinone I. Chin Med J (Engl). 2014;127(19):3396-405.
16. Pojda-Wilczek D. Retrospective analysis of pattern VEP results in different ocular and systemic diseases. Klin Oczna. 2010;112(7-9):205-9.
17. You Y, Klistorner A, Thie J, Graham SL. Latency delay of visual evoked potential is a real measurement of demyelination in a rat model of optic neuritis. Invest Ophthalmol Vis Sci. 2011;52(9):6911-8.
18. Quinn TA, Dutt M, Shindler KS. Optic neuritis and retinal ganglion cell loss in a chronic murine model of multiple sclerosis. Front Neurol. 2011;2:50.
19. Ren B, Zhang YX, Zhou HX, Sun FW, Zhang ZF, Wei Z, et al. Tanshinone IIA prevents the loss of nigrostriatal dopaminergic neurons by inhibiting NADPH oxidase and iNOS in the MPTP model of Parkinson's disease. J Neurol Sci. 2015;348(1-2):142-52.
20. Wang Y, Yang L, Yang D. Tanshinone IIA Rescued the Impairments of Primary Hippocampal Neurons Induced by BV2 Microglial Over-Activation. Neurochemical Res. 2015;40(7):1497-508.
21. Zhu S, Qian Y, Shi L, Yang W, Feng X, Li C, et al. Effect of tanshinone IIA on the change of calcium current induced by beta-amyloid protein 25-35 in neurons of nucleus basalis of Meynert. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2010;35(8):840-6.
22. Shi LL, Yang WN, Chen XL, Zhang JS, Yang PB, Hu XD, et al. The protective effects of tanshinone IIA on neurotoxicity induced by beta-amyloid protein through calpain and the p35/Cdk5 pathway in primary cortical neurons. Neurochem Internat. 2012;61(2):227-35.
23. Chirgwin SR, Nowling JM, Coleman SU, Klei TR. Brugia pahangi and Wolbachia: the kinetics of bacteria elimination, worm viability, and host responses following tetracycline treatment. Exp Parasitol. 2003;103(1-2):16-26.